Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck/NewLink Ebola vaccine 100% effective in Guinea trial

This article was originally published in Scrip

Executive Summary

Early results of an experimental Ebola vaccine being developed by Merck and its partner NewLink, which licensed the product from the Canadian government, showed the candidate, known as rVSV-ZEBOV, was 100% effective in protecting humans against the virus in a Phase III ring study being conducted in Guinea, researchers reported in the medical journal The Lancet on 31 July.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts